Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 17/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 6/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5748888 | 0.86 | DRD4 (0.73) | DRD4CYP2D6CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8291789 | 0.86 | DRD4 (0.73) | DRD4CYP2D6CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL13319146 | 0.86 | DRD4 (0.73) | DRD4CYP2D6CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL11687482 | 0.83 | KCNH2 (0.58) | DRD4DRD3DRD2 | |
| SCHEMBL17965934 | 0.81 | DRD4 (0.63) | DRD4CYP2D6CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL17965933 | 0.81 | DRD4 (0.63) | DRD4CYP2D6CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9228792 | 0.81 | SLC6A2 (0.50) | DRD4HRH3CYP2D6CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL10981595 | 0.79 | SLC6A2 (0.49) | DRD4HRH3CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL4481522 | 0.79 | DRD4 (0.63) | DRD4CYP2D6CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9599441 | 0.78 | DRD4 (0.59) | DRD4CYP2D6CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270877-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270877-A1 | IRE-1alpha INHIBITORS | XBP1, ERN1, ATF4 | DRD4 4845/4885HRH3 4488/4885CYP2D6 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.